On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: iStock
A new once-daily experimental pill slowed the decline in memory, thinking, and everyday functioning by 31% in some people with Alzheimer's disease in a Phase 3 trial.
Developed by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression by the equivalent of 3.5 months over one year.
Unlike existing dementia drugs, which primarily alleviate symptoms, AR1001 has shown potential to slow disease progression.
However, the benefit was significant only among patients who were not taking other dementia medications.
The company announced that "the trial had met its primary endpoint" at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, US.
Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For
The global trial involved 1,535 people with Alzheimer's disease across 230 sites in 13 countries.
Researchers assessed participants using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, judgment and the ability to perform everyday activities.
The findings showed:
The findings suggest that AR1001's effectiveness may depend on whether patients are taking other Alzheimer's medications.
Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, described the results as encouraging.
"These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms," Dr Richard said, the Daily Mail reported.
"Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third," he added.
Read More: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
AR1001 works differently from existing Alzheimer's treatments, such as lecanemab and donanemab, which target amyloid plaques in the brain.
Its active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, the compound used in Viagra to treat erectile dysfunction.
Both drugs inhibit an enzyme called phosphodiesterase-5 (PDE5). This helps relax blood vessels and improve blood flow.
Researchers believe AR1001 may have several effects in the brain, including:
Unlike some existing disease-modifying treatments that require infusions or injections, AR1001 is designed as a once-daily oral medication.
However, the drug is from the same family of medicines as Viagra and is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.
Most side effects reported during the trial were mild to moderate. Common side effects included diarrhoea, falls and dizziness.
Severe adverse events occurred in 10% of the treatment group and 9.8% of the placebo group.
Researchers also reported changes in biomarkers associated with Alzheimer's disease. Levels of the protein p-tau217 decreased in the monotherapy group, while cerebrospinal fluid cGMP levels increased in both treatment groups.
These findings offer clues about the drug's biological activity, although further research is needed to establish its effects.
However, the lack of a statistically significant benefit among people taking other Alzheimer's medications, adding that this required further investigation.
AR1001 is not yet available to the public and must undergo regulatory assessment before it can be prescribed.
Regulatory approval will depend on further evaluation, including whether the FDA considers the monotherapy results sufficient to support the drug's approval.
Credit: AI-generated image
L'Oréal USA and other manufacturers of chemical hair relaxers have reached a settlement with four women who alleged that years of using hair straightening products contributed to their gynaecological cancers.
The settlement was made during the first US trial involving these claims, bringing newfound attention to research examining the health risks of chemical hair treatments.
According to Reuters, the four women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, settled their lawsuits for an undisclosed amount. The trial was being held in Chicago.
The women had sued L'Oréal's US subsidiary and several other manufacturers in 2023 and 2024, alleging that prolonged exposure to chemical hair straighteners caused their cancers.
The settlement comes as litigation involving these products continues to surface. More than 12,700 related cases have been consolidated before a federal judge in Chicago.
The products, sold under brand names including Dark and Lovely and Optimum, have been widely marketed to Black women.
Also read: What Is Viral Heightmaxxing? US Doctors Warn Teen Boys Against Taking Cancer Drug To Grow Taller
L'Oréal has maintained that its products are safe. A company spokesperson said, "L’Oréal USA strictly follows all regulations in every market in which it operates and its products are always subject to a rigorous scientific evaluation of their safety."
The company has also argued that existing research does not establish that its products caused the conditions alleged in the lawsuits.
Scientific interest in the health effects of chemical hair straighteners increased after a 2022 study by researchers at the US National Institutes of Health (NIH).
Published in the Journal of the National Cancer Institute, the study examined data from 33,497 women aged 35-74 participating in the Sister Study.
Over an average follow-up of nearly 11 years, 378 cases of uterine cancer were identified.
Researchers found that women who reported using chemical hair straightening products more than four times in the preceding year had more than twice the risk of developing uterine cancer compared to women who had never used them.
The study estimated that 1.64% of women who had never used hair straighteners would develop uterine cancer by age 70, compared to 4.05% among frequent users.
However, researchers did not focus on the specific brands or chemical ingredients used, meaning they could not identify which substances might have contributed to the observed association.
Also read: Can A 'Sponge On A String' Test Help Detect Oesophageal Cancer Before Symptoms?
Other studies have also investigated links between chemical hair treatments and reproductive cancers.
A 2021 study published in Carcinogenesis found that frequent use of hair straighteners and relaxers may cause an increased risk of ovarian cancer. Women who used these products more than four times a year had approximately twice the risk compared with non-users.
Research from the Sister Study cohort has also showed an increased risk of breast cancer due to frequent hair straightener use especially among women who used the products regularly.
However, the findings are not the same across all studies. A 2025 systematic review examining evidence among Black women in the US concluded that the epidemiological evidence that is available did not support an increased risk of breast, ovarian or uterine cancers due to hair relaxer use.
Chemical hair relaxers and straighteners contain different substances depending on their formulation. Some products may contain endocrine-disrupting chemicals, including phthalates and parabens, which can interfere with hormonal activity.
Other concerning chemicals include formaldehyde and certain preservatives. Some straightening treatments can release formaldehyde, a recognised carcinogen.
Researchers have suggested that exposure to endocrine-disrupting chemicals could affect hormonal tissues.
Credit: AI-generated image
The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.
The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.
RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.
The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.
Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.
Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.
Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.
The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.
According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.
Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.
The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.
Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients
The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.
The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.
Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.
Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.
The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.
© $2026 Times Horizon Private Limited